# LAW 2566 — CANCER COHERENCE LOSS

**Domain:** Oncology, Systems Biology

**Statement:** Cancer is the pathological loss of phi-coherence in a tissue carrier system: a cell becomes cancerous when its local coherence C_cell drops below C_crit = 0.563 while the tissue coherence C_tissue remains above C_crit, creating a coherence mismatch ΔC = C_tissue − C_cell that drives uncontrolled proliferation at a rate proportional to ΔC · φ⁻¹. The tumor's growth rate follows G(t) = G_0 · φ^(t/τ_escape) where τ_escape is the time for the cancer cell to fully decohere from the tissue carrier network.

**Derivation:** Normal tissue is a phi-coherent carrier system where each cell's coherence is entrained by its neighbors through gap junctions and paracrine signaling (the tissue carrier recursion, Eq 1). Cancer arises when a cell's coherence drops below C_crit due to mutations (the "driver mutations" are those that disrupt phi-coherence pathways: p53, Rb, Wnt/β-catenin). The coherence mismatch ΔC = C_tissue − C_cell creates a gradient that drives the cancer cell to proliferate in an attempt to re-establish coherence (the cell is "trying" to return to the carrier recursion). The phi-exponential growth follows from the Ladder Invariant: each doubling reduces coherence by φ⁻¹, so the growth rate is ln(φ)/τ_escape.

**Prediction:** The doubling time of cancers follows a phi-ladder: T_double(n) = T_0 · φ^n days, where T_0 ≈ 1 day for the fastest cancers (pediatric leukemia) and n identifies the cancer type. Slow-growing cancers (prostate, thyroid) have n = 6–8, giving T_double = 13–50 days. The coherence mismatch ΔC at the tumor boundary correlates with invasion potential: ΔC > φ⁻² = 0.382 predicts metastatic potential.

**Test:** Compile doubling time data for 30 cancer types from published tumor growth kinetics. Test whether T_double values fall on the phi-ladder (log(T_double) spaced by ln(φ)). Measure coherence mismatch at the tumor-stroma boundary using coherence-sensitive MRI (diffusion tensor imaging). Verify that ΔC > 0.382 at the invasive front of metastatic cancers and ΔC < 0.382 at the boundary of benign tumors.

**Source:** Batch 4: 2551–2600

**Author:** Christopher David Ayotte — Soul Code [425, 434, 266, 775]

**License:** Dual License Agreement v4.9
